Pentraxin 3 is reduced in bipolar disorder

Faith Dickerson, Cassie Stallings, Andrea Origoni, Emily Katsafanas, Lucy Ab Schweinfurth, Christina Lg Savage, Sunil Khushalani, Robert H Yolken

Research output: Contribution to journalArticle

Abstract

Objective: Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population. Methods: Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non-psychiatric controls. Linear regression models were used to compare the pentraxin 3 levels in each of the psychiatric groups to that in the control group, adjusting for demographic and clinical variables. Logistic regression models were used to calculate the odds ratios associated with levels of pentraxin 3 which differed from specified levels of the control group. Results: The sample consisted of 831 individuals: 256 with bipolar disorder, 309 with schizophrenia, and 266 without a psychiatric disorder. The levels of pentraxin 3 in the bipolar disorder, but not in the schizophrenia, group were significantly lower than those of controls, adjusting for age, gender, race, maternal education, smoking status, and body mass index (t = -3.78, p <0.001). The individuals with bipolar disorder also had significantly increased odds of having low levels of pentraxin 3 relative to both the 10th and 25th percentile level of the controls and significantly decreased odds of having a level greater than the 75th and the 90th percentile level of the controls, adjusting for the same covariates. Conclusions: Individuals with bipolar disorder have low levels of pentraxin 3 which may reflect impaired innate immunity. An increased understanding of the role of innate immunity in the etiopathogenesis of bipolar disorder might lead to new modalities for the diagnosis and treatment of this disorder.

Original languageEnglish (US)
Pages (from-to)409-414
Number of pages6
JournalBipolar Disorders
Volume17
Issue number4
DOIs
StatePublished - Jun 1 2015

Fingerprint

Bipolar Disorder
Innate Immunity
Schizophrenia
Psychiatry
Linear Models
Logistic Models
Control Groups
PTX3 protein
Body Mass Index
Smoking
Odds Ratio
Mothers
Demography
Education
Population

Keywords

  • Bipolar disorder
  • Innate immunity
  • Pentraxin 3
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Dickerson, F., Stallings, C., Origoni, A., Katsafanas, E., Schweinfurth, L. A., Savage, C. L., ... Yolken, R. H. (2015). Pentraxin 3 is reduced in bipolar disorder. Bipolar Disorders, 17(4), 409-414. https://doi.org/10.1111/bdi.12281

Pentraxin 3 is reduced in bipolar disorder. / Dickerson, Faith; Stallings, Cassie; Origoni, Andrea; Katsafanas, Emily; Schweinfurth, Lucy Ab; Savage, Christina Lg; Khushalani, Sunil; Yolken, Robert H.

In: Bipolar Disorders, Vol. 17, No. 4, 01.06.2015, p. 409-414.

Research output: Contribution to journalArticle

Dickerson, F, Stallings, C, Origoni, A, Katsafanas, E, Schweinfurth, LA, Savage, CL, Khushalani, S & Yolken, RH 2015, 'Pentraxin 3 is reduced in bipolar disorder', Bipolar Disorders, vol. 17, no. 4, pp. 409-414. https://doi.org/10.1111/bdi.12281
Dickerson F, Stallings C, Origoni A, Katsafanas E, Schweinfurth LA, Savage CL et al. Pentraxin 3 is reduced in bipolar disorder. Bipolar Disorders. 2015 Jun 1;17(4):409-414. https://doi.org/10.1111/bdi.12281
Dickerson, Faith ; Stallings, Cassie ; Origoni, Andrea ; Katsafanas, Emily ; Schweinfurth, Lucy Ab ; Savage, Christina Lg ; Khushalani, Sunil ; Yolken, Robert H. / Pentraxin 3 is reduced in bipolar disorder. In: Bipolar Disorders. 2015 ; Vol. 17, No. 4. pp. 409-414.
@article{810833eddaba4fe580390522e2f9e56d,
title = "Pentraxin 3 is reduced in bipolar disorder",
abstract = "Objective: Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population. Methods: Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non-psychiatric controls. Linear regression models were used to compare the pentraxin 3 levels in each of the psychiatric groups to that in the control group, adjusting for demographic and clinical variables. Logistic regression models were used to calculate the odds ratios associated with levels of pentraxin 3 which differed from specified levels of the control group. Results: The sample consisted of 831 individuals: 256 with bipolar disorder, 309 with schizophrenia, and 266 without a psychiatric disorder. The levels of pentraxin 3 in the bipolar disorder, but not in the schizophrenia, group were significantly lower than those of controls, adjusting for age, gender, race, maternal education, smoking status, and body mass index (t = -3.78, p <0.001). The individuals with bipolar disorder also had significantly increased odds of having low levels of pentraxin 3 relative to both the 10th and 25th percentile level of the controls and significantly decreased odds of having a level greater than the 75th and the 90th percentile level of the controls, adjusting for the same covariates. Conclusions: Individuals with bipolar disorder have low levels of pentraxin 3 which may reflect impaired innate immunity. An increased understanding of the role of innate immunity in the etiopathogenesis of bipolar disorder might lead to new modalities for the diagnosis and treatment of this disorder.",
keywords = "Bipolar disorder, Innate immunity, Pentraxin 3, Schizophrenia",
author = "Faith Dickerson and Cassie Stallings and Andrea Origoni and Emily Katsafanas and Schweinfurth, {Lucy Ab} and Savage, {Christina Lg} and Sunil Khushalani and Yolken, {Robert H}",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/bdi.12281",
language = "English (US)",
volume = "17",
pages = "409--414",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "4",

}

TY - JOUR

T1 - Pentraxin 3 is reduced in bipolar disorder

AU - Dickerson, Faith

AU - Stallings, Cassie

AU - Origoni, Andrea

AU - Katsafanas, Emily

AU - Schweinfurth, Lucy Ab

AU - Savage, Christina Lg

AU - Khushalani, Sunil

AU - Yolken, Robert H

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objective: Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population. Methods: Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non-psychiatric controls. Linear regression models were used to compare the pentraxin 3 levels in each of the psychiatric groups to that in the control group, adjusting for demographic and clinical variables. Logistic regression models were used to calculate the odds ratios associated with levels of pentraxin 3 which differed from specified levels of the control group. Results: The sample consisted of 831 individuals: 256 with bipolar disorder, 309 with schizophrenia, and 266 without a psychiatric disorder. The levels of pentraxin 3 in the bipolar disorder, but not in the schizophrenia, group were significantly lower than those of controls, adjusting for age, gender, race, maternal education, smoking status, and body mass index (t = -3.78, p <0.001). The individuals with bipolar disorder also had significantly increased odds of having low levels of pentraxin 3 relative to both the 10th and 25th percentile level of the controls and significantly decreased odds of having a level greater than the 75th and the 90th percentile level of the controls, adjusting for the same covariates. Conclusions: Individuals with bipolar disorder have low levels of pentraxin 3 which may reflect impaired innate immunity. An increased understanding of the role of innate immunity in the etiopathogenesis of bipolar disorder might lead to new modalities for the diagnosis and treatment of this disorder.

AB - Objective: Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population. Methods: Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non-psychiatric controls. Linear regression models were used to compare the pentraxin 3 levels in each of the psychiatric groups to that in the control group, adjusting for demographic and clinical variables. Logistic regression models were used to calculate the odds ratios associated with levels of pentraxin 3 which differed from specified levels of the control group. Results: The sample consisted of 831 individuals: 256 with bipolar disorder, 309 with schizophrenia, and 266 without a psychiatric disorder. The levels of pentraxin 3 in the bipolar disorder, but not in the schizophrenia, group were significantly lower than those of controls, adjusting for age, gender, race, maternal education, smoking status, and body mass index (t = -3.78, p <0.001). The individuals with bipolar disorder also had significantly increased odds of having low levels of pentraxin 3 relative to both the 10th and 25th percentile level of the controls and significantly decreased odds of having a level greater than the 75th and the 90th percentile level of the controls, adjusting for the same covariates. Conclusions: Individuals with bipolar disorder have low levels of pentraxin 3 which may reflect impaired innate immunity. An increased understanding of the role of innate immunity in the etiopathogenesis of bipolar disorder might lead to new modalities for the diagnosis and treatment of this disorder.

KW - Bipolar disorder

KW - Innate immunity

KW - Pentraxin 3

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84930393405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930393405&partnerID=8YFLogxK

U2 - 10.1111/bdi.12281

DO - 10.1111/bdi.12281

M3 - Article

VL - 17

SP - 409

EP - 414

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 4

ER -